Skip to main content
  • Poster presentation
  • Published:

Urine TIMP2 × IGFBP7 increases 24 hours before severe AKI


We recently reported a 728-patient multicenter study (Sapphire) where a biomarker combination of tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) were validated for risk stratification for moderate or severe acute kidney injury (AKI) KDIGO stage 2 and 3 [1].


We subsequently selected two clinical cutoff values for the TIMP2 × IGFBP7 combination from the Sapphire dataset, one (0.3) with high sensitivity (89%) (specificity = 50%) and one (2.0) with high specificity (95%) (sensitivity = 42%) for the development of AKI KDIGO stage 2 and 3 within 12 hours of study enrolment. We examined the timing of change in TIMP2 × IGFBP7 relative to change in creatinine using the sign test.


TIMP2 × IGFBP7 results were available for 178 patients who developed AKI stage 2 or 3. The median TIMP2 × IGFBP7 result was significantly greater than the cutoff value of 0.3 from 24 hours before to 24 hours after AKI 2 or 3 (P < 0.01) (Figure 1). Conversely, median serum creatinine was not different from baseline prior to development of AKI 2 or 3.

Figure 1
figure 1

NC, Nephrocheck (TIMP2 × IGFBP7); Cr, creatinine.


The TIMP2 × IGFBP7 biomarker combination identifies patients who ultimately develop moderate or severe AKI 24 hours earlier than serum creatinine.


  1. Kashani K, et al.: Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013, 17: R25. 10.1186/cc12503

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations



Rights and permissions

Reprints and permissions

About this article

Cite this article

Ostermann, M., Chawla, L., Forni, L. et al. Urine TIMP2 × IGFBP7 increases 24 hours before severe AKI. Crit Care 18 (Suppl 1), P380 (2014).

Download citation

  • Published:

  • DOI: